Atara Biotherapeutics Inc
ATRA11.559USD
+0.009+0.08%
交易中 （美东）报价延迟15分钟
68.48M总市值
亏损市盈率 TTM
关于 Atara Biotherapeutics Inc 公司
Atara Biotherapeutics, Inc. 是一家同种异体 T 细胞免疫疗法公司。该公司是 T 细胞免疫疗法的开发商，利用其新型同种异体 Epstein-Barr 病毒 (EBV) T 细胞平台为患有严重疾病（包括实体瘤、血液系统癌症和自身免疫性疾病）的患者开发变革性疗法。其产品线包括 Ebvallo (Tab-cel)、ATA3219。该公司的 T 细胞免疫疗法 tab-cel (tabelecleucel) 正处于 III 期开发阶段，用于治疗利妥昔单抗或利妥昔单抗联合化疗失败的 EBV 驱动的移植后淋巴增生性疾病 (EBV+ PTLD) 患者，以及其他 EBV 驱动的疾病。其 ATA3219 正处于第 1 阶段开发，旨在开发一种潜在产品，旨在针对 B 细胞恶性肿瘤和自身免疫性疾病，基于下一代 1XX 共刺激结构域和 EBV T 细胞的先天优势作为同种异体 CAR T 平台的基础。
公司简介
公司代码ATRA
公司名称Atara Biotherapeutics Inc
上市日期Oct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
员工数量153
证券类型Ordinary Share
年结日Oct 16
公司地址1280 Rancho Conejo Blvd
城市THOUSAND OAKS
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编91320
电话18056234211
网址https://www.atarabio.com/
公司代码ATRA
上市日期Oct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Pascal Touchon
Dr. Pascal Touchon
Chairman of the Board
Chairman of the Board
46.22K
+20.39%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Dr. Maria Grazia Roncarolo, M.D.
Dr. Maria Grazia Roncarolo, M.D.
Independent Director
Independent Director
11.37K
+221.13%
Mr. Ameet Mallik
Mr. Ameet Mallik
Independent Director
Independent Director
10.93K
+252.52%
Amber Daugherty
Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Pascal Touchon
Dr. Pascal Touchon
Chairman of the Board
Chairman of the Board
46.22K
+20.39%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Dr. Maria Grazia Roncarolo, M.D.
Dr. Maria Grazia Roncarolo, M.D.
Independent Director
Independent Director
11.37K
+221.13%
Mr. Ameet Mallik
Mr. Ameet Mallik
Independent Director
Independent Director
10.93K
+252.52%
Amber Daugherty
Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Panacea Venture
19.88%
Adiumentum Capital Fund I LP
19.20%
EcoR1 Capital, LLC
8.56%
Redmile Group, LLC
6.60%
The Vanguard Group, Inc.
2.85%
Other
42.91%
持股股东
持股股东
占比
Panacea Venture
19.88%
Adiumentum Capital Fund I LP
19.20%
EcoR1 Capital, LLC
8.56%
Redmile Group, LLC
6.60%
The Vanguard Group, Inc.
2.85%
Other
42.91%
股东类型
持股股东
占比
Venture Capital
19.88%
Investment Advisor/Hedge Fund
19.74%
Corporation
19.20%
Investment Advisor
5.52%
Individual Investor
3.21%
Research Firm
3.03%
Hedge Fund
2.87%
Bank and Trust
0.07%
Other
26.48%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
241
4.96M
74.12%
-1.65M
2025Q1
282
4.01M
65.40%
-1.34M
2024Q4
299
3.71M
64.35%
-1.71M
2024Q3
318
3.77M
66.12%
-1.71M
2024Q2
338
3.34M
67.67%
-2.05M
2024Q1
355
3.52M
73.26%
-1.12M
2023Q4
356
2.78M
67.54%
-1.84M
2023Q3
355
3.69M
90.14%
-612.93K
2023Q2
363
3.86M
98.31%
-820.50K
2023Q1
367
4.34M
112.70%
-175.57K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Panacea Venture
1.33M
19.88%
+780.66K
+141.94%
May 16, 2025
Adiumentum Capital Fund I LP
1.28M
19.2%
+151.14K
+13.33%
May 16, 2025
EcoR1 Capital, LLC
573.18K
8.56%
+41.05K
+7.71%
Mar 31, 2025
Redmile Group, LLC
441.70K
6.6%
--
--
May 16, 2025
The Vanguard Group, Inc.
190.76K
2.85%
+11.98K
+6.70%
Mar 31, 2025
BofA Global Research (US)
187.30K
2.8%
-17.87K
-8.71%
Mar 31, 2025
Acadian Asset Management LLC
115.11K
1.72%
-9.36K
-7.52%
Mar 31, 2025
Vestal Point Capital, LP
94.08K
1.41%
-30.91K
-24.73%
Mar 31, 2025
Staley Capital Advisers, Inc.
80.00K
1.2%
+30.00K
+60.00%
Mar 31, 2025
Tang Capital Management, LLC
75.20K
1.12%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
Harbor Human Capital Factor US Small Cap ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
Harbor Human Capital Factor US Small Cap ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Schwab U.S. Broad Market ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
公告日期
类型
比率
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
